VisiRose

Executive Summary

VisiRose is a San Diego-based biotechnology startup pioneering a novel photodynamic antimicrobial therapy (PDAT) for serious eye infections, specifically infectious keratitis. Leveraging research from the University of Miami's Bascom Palmer Eye Institute, the company's proprietary Rose Bengal PDAT offers a non-invasive, broad-spectrum treatment that addresses the growing threat of antimicrobial resistance. Founded in 2019, VisiRose aims to restore vision by providing an alternative to conventional antibiotics and antifungals, which are increasingly ineffective against resistant pathogens. The technology uses a photosensitizing dye activated by light to selectively destroy microbial cells while minimizing damage to ocular tissue. Despite being in early stages with no disclosed funding rounds or regulatory milestones, the company's strong academic backing and clear unmet medical need position it as a promising player in ophthalmic medical devices. Key challenges include navigating FDA regulatory pathways, demonstrating clinical efficacy in rigorous trials, and securing manufacturing scale-up.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 Clinical Trial for Infectious Keratitis60% success
• Q2 2026FDA Breakthrough Device Designation or Orphan Drug Status50% success
• Q1 2027Strategic Partnership or Licensing Deal with Major Ophthalmic Company40% success